Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages 409-416

  Ben Shimol, Shalom ^a   Greenberg, David ^a   Hazan, Guy ^a   Givon Lavi, Noga ^a   Gottesman, Giora ^b   Grisaru Soen, Galia ^c   Dagan, Ron ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

bacteremic pneumonia; children; Impact; invasive pneumococcal disease; pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

AGE DISTRIBUTION; ARTICLE; BACTEREMIC PNEUMONIA; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; CELLULITIS; CHILD; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MASTOIDITIS; MENINGITIS; MORBIDITY; OSTEOMYELITIS; PATHOGENESIS; PERICARDITIS; PERITONITIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEASONAL VARIATION; SEPSIS; SEROTYPE; SINUSITIS; BACTEREMIA; CLASSIFICATION; COMPLICATION; EPIDEMIOLOGICAL MONITORING; FEMALE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; ISRAEL; MALE; MENINGITIS, PNEUMOCOCCAL; MICROBIOLOGY; NEWBORN; PNEUMONIA, PNEUMOCOCCAL; PRESCHOOL CHILD; SEASON; STREPTOCOCCUS PNEUMONIAE;

AGE DISTRIBUTION; BACTEREMIA; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISRAEL; MALE; MENINGITIS, PNEUMOCOCCAL; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; SEASONS; SEROGROUP; STREPTOCOCCUS PNEUMONIAE;

EID: 84937556539     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000604     Document Type: Article

References (37)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
2. Shah SS, Dugan MH, Bell LM, et al. Blood cultures in the emergency department evaluation of childhood pneumonia. Pediatr Infect Dis J. 2011;30:475-479.
3. Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002;34:434-440.
4. Picard E, Joseph L, Goldberg S, et al. Predictive factors of morbidity in childhood parapneumonic effusion-Associated pneumonia: A retrospective study. Pediatr Infect Dis J. 2010;29:840-843.
5. Hoff SJ, Neblett WW, Edwards KM, et al. Parapneumonic empyema in children: decortication hastens recovery in patients with severe pleural infections. Pediatr Infect Dis J. 1991;10:194-199.
6. Esposito S, Marchese A, Tozzi AE, et al. Italian Pneumococcal CAP Group. Bacteremic pneumococcal community-Acquired pneumonia in children less than 5 years of age in Italy. Pediatr Infect Dis J. 2012;31:705-710.
7. Eastham KM, Freeman R, Kearns AM, et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax. 2004;59:522-525.
8. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-Acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med. 1999;160:397-405.
9. Ruiz-Gonzalez A, Falguera M, Nogues A, et al. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-Acquired pneumonia. Am J Med. 1999;106:385-390.
10. Michelow IC, Lozano J, Olsen K, et al. Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin Infect Dis. 2002;34:E1-11.
11. Ben-Shimol S, Dagan R, Givon-Lavi N, et al. [Community acquired pneumonia (CAP) in children younger than 5 years of age in southern Israel]. Harefuah. 2010;149:137-142, 196.
12. Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med. 2000;15:638-646.
13. Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Israeli Bacteremia and Meningitis Active Surveillance Group. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012;30:6600-6607.
14. Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community-Acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med. 1987;62:195-220.
15. Molander V, Elisson C, Balaji V, et al. Invasive pneumococcal infections in Vellore, India: clinical characteristics and distribution of serotypes. BMC Infect Dis. 2013;13:532.
16. Lee MR, Chen CM, Chuang TY, et al. Capsular serotypes and antimicrobial susceptibilities of Streptococcus pneumoniae causing invasive pneumococcal disease from 2009-2012 with an emphasis on serotype 19A in bacteraemic pneumonia and empyema and beta-lactam resistance. Int J Antimicrob Agents. 2013;42:395-402.
17. Lai CY, Huang LM, Lee PY, et al. Comparison of invasive pneumococcal disease caused by serotype 19A and non-19A pneumococci in children: more empyema in serotype 19A invasive pneumococcal disease. J Microbiol Immunol Infect. 2014;47:23-27.
18. Berg S, Trollfors B, Persson E, et al. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis. 2006;38: 427-432.
19. The Central Bureau of Statistics. Statistical Abstract of Israel No. 63, 2012. Available at: http://www.cbs.gov.il/shnaton63/st02-10x.pdf. Accessed August 2014.
20. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294:202-210.
21. Greenberg D, Givon-Lavi N, Porat N, et al. Streptococcus pneumoniae nasopharyngeal carriage among school children 6-10 years old from 2 ethnic populations, 12-18 months after introduction of the 7-valent pneumococcal conjugate vaccine into the national immunization program [Abst. 660]. In: The 49th Annual Meeting of the Infectious Diseases Society of America, Boston, MA, October 2011.
22. Dagan R, Landau D, Haikin H, et al. Hospitalization of Jewish and Bedouin infants in southern Israel for bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J. 1993;12:381-386.
23. Fraser D, Givon-Lavi N, Bilenko N, et al. A decade (1989-1998) of pediatric invasive pneumococcal disease in 2 populations residing in 1 geographic location: implications for vaccine choice. Clin Infect Dis. 2001;33:421-427.
24. Weil-Olivier C, van der Linden M, de Schutter I, et al. Prevention of pneumococcal diseases in the post-seven valent vaccine era: A European perspective. BMC Infect Dis. 2012;12:207.
25. Sandgren A, Albiger B, Orihuela CJ, et al. Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans. J Infect Dis. 2005;192:791-800.
26. Browall S, Norman M, Tångrot J, et al. Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis. 2014;209:377-388.
27. Shouval DS, Greenberg D, Givon-Lavi N, et al. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J. 2006;25:602-607.
28. Brueggemann AB, Peto TE, Crook DW, et al. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis. 2004;190:1203-1211.
29. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine. 2007;25:2406-2412.
30. Mistry RD, Wedin T, Balamuth F, et al. Emergency department epidemiology of pneumococcal bacteremia in children since the institution of widespread PCV7 vaccination. J Emerg Med. 2013;45:813-820.
31. Liu C, Xiong X, Xu W, et al. Serotypes and patterns of antibiotic resistance in strains causing invasive pneumococcal disease in children less than 5 years of age. PLoS One. 2013;8:e54254.
32. Thomas MF, Sheppard CL, Guiver M, et al. Emergence of pneumococcal 19A empyema in UK children. Arch Dis Child. 2012;97:1070-1072.
33. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: Associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009;49:e23-e29.
34. Greenberg D, Givon-Lavi N, Newman N, et al. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric pneumonia as a means to estimate serotype disease potential. Pediatr Infect Dis J. 2011;30:227-233.
35. Ampofo K, Pavia AT, Chris S, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: A case for continuous surveillance. Pediatr Infect Dis J. 2012;31:228-234.
36. Weinberger DM, Grant LR, Steiner CA, et al. Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. Clin Infect Dis. 2014;58:188-194.
37. Ben-Shimol S, Greenberg D, Hazan G, et al. Viral lower respiratory tract infections seasonality coincides with both bacteremic pneumococcal pneumonia and non-bacteremic alveolar pneumonia, but not with non-BPP invasive pneumococcal diseases [G-284]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, 2014, Washington, DC.